ArticleRetina (Philadelphia, Pa.)2020
VASOPROLIFERATIVE TUMORS IN INTERMEDIATE UVEITIS.
Article in Retina (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 22 citations in OpenAlex.
- Vasoproliferative Tumors of the Retina: Pathophysiology, Clinical Features, and Treatment Approaches.Ocular oncology and pathology · 2026Article
- Outcomes of Vitrectomy for Macular Pathologies Associated with Idiopathic Vasoproliferative Retinal Tumor.Journal of clinical medicine · 2025Article
- Vasoproliferative Tumor Secondary to Sarcoidosis-Associated Intermediate Uveitis.Turkish journal of ophthalmology · 2024Article
- Macular sequelae in vasoproliferative tumors: results of surgical approach.International ophthalmology · 2021Article
- Retinal vasoproliferative tumor in intermediate uveitis: A case report.Annals of medicine and surgery (2012) · 2020Article
- Nonpigmented Adenoma of the Retinal Pigment Epithelium Mimicking a Retinal Vasoproliferative Tumor Managed With Endoresection.Journal of vitreoretinal diseasesArticle
- Stand-alone pars plana vitrectomy versus pars plana vitrectomy with retinopexy for retinal vasoproliferative tumors.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
Abstract
purposeTo describe patients with intermediate uveitis complicated by vasoproliferative tumors (VPTs).
methodsData were collected at seven Uveitis/Ocular Oncology centers on demographic, ophthalmic findings at baseline and at follow-up, and on imaging. The therapeutic intervention, final visual acuity, and duration of follow-up were recorded.
resultsA total of 36 eyes from 34 patients (12 men, 22 women; mean age 35.3 ± 14.2 years) were included in this study. Visual acuity at presentation ranged from 20/40 to counting fingers. At the time of VPT diagnosis, intermediate uveitis was active in all eyes. The mean VPT thickness was 3.06 ± 0.86 mm. Local treatment to the VPT was provide in 22 eyes (61.1%) and no local treatment to the VPT in 14 eyes (38.9%). After the VPT was detected, systemic or local treatment for the inflammation was initiated and on follow-up FAs 94.4% of the eyes showed resolution of the vascular leakage. During follow-up of 35.8 months, the 22 VPTs treated locally had a reduction in the tumor thickness to 1.25 mm, whereas the 14 VPTs untreated remained stable (final mean tumor thickness 2.65 mm).
conclusionThe presence of active intermediate uveitis accompanied by VPTs suggests the need for an aggressive uveitis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.